Ionis Pharmaceuticals/$IONS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Ticker
$IONS
Sector
Primary listing
Employees
1,402
Headquarters
Website
IONS Metrics
BasicAdvanced
$13bn
-
-$2.02
0.38
-
Price and volume
Market cap
$13bn
Beta
0.38
52-week high
$86.74
52-week low
$32.00
Average daily volume
1.8m
Financial strength
Current ratio
4.098
Quick ratio
2.862
Long term debt to equity
440.813
Total debt to equity
573.116
Interest coverage (TTM)
-3.91%
Profitability
EBITDA (TTM)
-339.509
Gross margin (TTM)
10.94%
Net profit margin (TTM)
-30.90%
Operating margin (TTM)
-33.38%
Effective tax rate (TTM)
-0.58%
Revenue per employee (TTM)
$750,000
Management effectiveness
Return on assets (TTM)
-7.05%
Return on equity (TTM)
-67.62%
Valuation
Price to revenue (TTM)
11.568
Price to book
25.61
Price to tangible book (TTM)
25.58
Price to free cash flow (TTM)
-12.516
Free cash flow yield (TTM)
-7.99%
Free cash flow per share (TTM)
-6.055
Growth
Revenue change (TTM)
47.53%
Earnings per share change (TTM)
-32.47%
3-year revenue growth (CAGR)
22.48%
10-year revenue growth (CAGR)
15.15%
3-year earnings per share growth (CAGR)
-4.36%
10-year earnings per share growth (CAGR)
6.10%
What the Analysts think about IONS
Analyst ratings (Buy, Hold, Sell) for Ionis Pharmaceuticals stock.
IONS Financial Performance
Revenues and expenses
IONS Earnings Performance
Company profitability
IONS News
AllArticlesVideos
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
MarketBeat·5 days ago
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease
Business Wire·1 week ago
Ionis to host 2026 virtual Annual Meeting of Stockholders
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs